{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,4,27]],"date-time":"2024-04-27T01:40:03Z","timestamp":1714182003562},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2012,7,19]],"date-time":"2012-07-19T00:00:00Z","timestamp":1342656000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Z. Rheumatol."],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1007\/s00393-012-0997-5","type":"journal-article","created":{"date-parts":[[2012,7,17]],"date-time":"2012-07-17T15:59:51Z","timestamp":1342540791000},"page":"504-514","source":"Crossref","is-referenced-by-count":5,"title":["Skleromyx\u00f6dem","Scleromyxedema"],"prefix":"10.1007","volume":"71","author":[{"given":"A.","family":"Kreuter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"St\u00fccker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.G.A.","family":"Kolios","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Altmeyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"M\u00f6llenhoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,7,19]]},"reference":[{"key":"997_CR1","first-page":"569","volume":"37","author":"Dubreuilh","year":"1906","unstructured":"Dubreuilh W (1906) Fibromes miliaires folliculaires: sclerodemie consecutive. Ann Dermatol Syph 37:569\u2013572","journal-title":"Ann Dermatol Syph"},{"key":"997_CR2","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/BF01949029","volume":"92","author":"Reitmann","year":"1908","unstructured":"Reitmann K (1908) \u00dcber eine eigenartige, der Sklerodermie nahestehende Affektion. Arch Dermatol Syph 92:417\u2013424","journal-title":"Arch Dermatol Syph"},{"key":"997_CR3","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/jid.1953.25","volume":"20","author":"Montgomery","year":"1953","unstructured":"Montgomery H, Underwood LJ (1953) Lichen myxedematosus (differentiation from cutaneous myxedemas or mucoid states). J Invest Dermatol 20:213\u2013236","journal-title":"J Invest Dermatol"},{"key":"997_CR4","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/BF00362184","volume":"199","author":"Gottron","year":"1954","unstructured":"Gottron HA (1954) Skleromyx\u00f6dem (eine eigenartige Erscheinungsform von Myxothesaurodermie). Arch Dermatol Syph 199:71\u201391","journal-title":"Arch Dermatol Syph"},{"key":"997_CR5","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1046\/j.1365-4362.2003.01565.x","volume":"42","author":"Pomann","year":"2003","unstructured":"Pomann JJ, Rudner EJ (2003) Scleromyxedema revisited. Int J Dermatol 42:31\u201335","journal-title":"Int J Dermatol"},{"key":"997_CR6","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1067\/mjd.2001.111630","volume":"44","author":"Rongioletti","year":"2001","unstructured":"Rongioletti F, Rebora A (2001) Updated classification of papular mucinosis, lichen myxedematosus, and scleromyxedema. J Am Acad Dermatol 44:273\u2013281","journal-title":"J Am Acad Dermatol"},{"key":"997_CR7","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1111\/j.1610-0387.2007.06311.x","volume":"5","author":"Fabri","year":"2007","unstructured":"Fabri M, Hunzelmann N (2007) Differential diagnosis of scleroderma and pseudoscleroderma. J Dtsch Dermatol Ges 5:977\u2013984","journal-title":"J Dtsch Dermatol Ges"},{"key":"997_CR8","first-page":"171","volume":"12","author":"Yaron","year":"1985","unstructured":"Yaron M, Yaron I, Yust I, Brenner S (1985) Lichen myxedematosus (scleromyxedema) serum stimulates hyaluronic acid and prostaglandin E production by human fibroblasts. J Rheumatol 12:171\u2013175","journal-title":"J Rheumatol"},{"key":"997_CR9","first-page":"837","volume":"16","author":"Ferrarini","year":"1989","unstructured":"Ferrarini M, Helfrich DJ, Walker ER et al (1989) Scleromyxedema serum increases proliferation but not the glycosaminoglycan synthesis of dermal fibroblasts. J Rheumatol 16:837\u2013841","journal-title":"J Rheumatol"},{"key":"997_CR10","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1126\/science.622555","volume":"199","author":"Harper","year":"1978","unstructured":"Harper RA, Rispler J (1978) Lichen myxedematosus serum stimulates human skin fibroblast proliferation. Science 199:545\u2013547","journal-title":"Science"},{"key":"997_CR11","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0190-9622(99)70383-X","volume":"41","author":"Bata-Csorgo","year":"1999","unstructured":"Bata-Csorgo Z, Husz S, Foldes M et al (1999) Scleromyxedema. J Am Acad Dermatol 41:343\u2013346","journal-title":"J Am Acad Dermatol"},{"key":"997_CR12","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1111\/j.1365-2133.2003.05682.x","volume":"149","author":"Kulczycki","year":"2003","unstructured":"Kulczycki A, Nelson M, Eisen A, Heffernan M (2003) Scleromyxoedema: treatment of cutaneous and systemic manifestations with high-dose intravenous immunoglobulin. Br J Dermatol 149:1276\u20131281","journal-title":"Br J Dermatol"},{"key":"997_CR13","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0190-9622(98)70567-5","volume":"38","author":"Godby","year":"1998","unstructured":"Godby A, Bergstresser PR, Chaker B, Pandya AG (1998) Fatal scleromyxedema: report of a case and review of the literature. J Am Acad Dermatol 38:289\u2013294","journal-title":"J Am Acad Dermatol"},{"key":"997_CR14","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/0190-9622(95)90007-1","volume":"33","author":"Dinneen","year":"1995","unstructured":"Dinneen AM, Dicken CH (1995) Scleromyxedema. J Am Acad Dermatol 33:37\u201343","journal-title":"J Am Acad Dermatol"},{"key":"997_CR15","doi-asserted-by":"crossref","unstructured":"Gabriel SE, Perry HO, Oleson GB, Bowles CA (1988) Scleromyxedema: a scleroderma-like disorder with systemic manifestations. Medicine (Baltimore) 67:58\u201365","DOI":"10.1097\/00005792-198801000-00004"},{"key":"997_CR16","doi-asserted-by":"crossref","unstructured":"Blum M, Wigley FM, Hummers LK (2008) Scleromyxedema: a case series highlighting long-term outcomes of treatment with intravenous immunoglobulin (IVIG). Medicine (Baltimore) 87:10\u201320","DOI":"10.1097\/MD.0b013e3181630835"},{"key":"997_CR17","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/0190-9622(93)70021-K","volume":"28","author":"Webster","year":"1993","unstructured":"Webster GF, Matsuoka LY, Burchmore D (1993) The association of potentially lethal neurologic syndromes with scleromyxedema (papular mucinosis). J Am Acad Dermatol 28:105\u2013108","journal-title":"J Am Acad Dermatol"},{"key":"997_CR18","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1001\/archderm.1956.01550090033007","volume":"74","author":"McCuistion","year":"1956","unstructured":"McCuistion CH, Schoch EP Jr (1956) Autopsy findings in lichen myxedematosus. Arch Dermatol 74:259\u2013262","journal-title":"Arch Dermatol"},{"key":"997_CR19","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1212\/WNL.46.6.1778","volume":"46","author":"River","year":"1996","unstructured":"River Y, Levy I, Gilead L et al (1996) Fever, convulsions and coma in scleromyxedema: a \u201edermatoneuro syndrome\u201c. Neurology 46(6):1778\u20131799","journal-title":"Neurology"},{"key":"997_CR20","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/S0190-9622(00)90274-3","volume":"42","author":"Gonzalez","year":"2000","unstructured":"Gonzalez J, Palangio M, Schwartz J et al (2000) Scleromyxedema with dermatoneuro syndrome. J Am Acad Dermatol 42:927\u2013928","journal-title":"J Am Acad Dermatol"},{"key":"997_CR21","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.jaad.2008.11.013","volume":"60","author":"Rey","year":"2009","unstructured":"Rey JB, Luria RB (2009) Treatment of scleromyxedema and the dermatoneuro syndrome with intravenous immunoglobulin. J Am Acad Dermatol 60:1037\u20131041","journal-title":"J Am Acad Dermatol"},{"key":"997_CR22","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/j.1749-6632.1998.tb09682.x","volume":"845","author":"Yu","year":"1998","unstructured":"Yu RK, Ariga T (1998) The role of glycosphingolipids in neurological disorders. Mechanisms of immune action. Ann N Y Acad Sci 845:285\u2013306","journal-title":"Ann N Y Acad Sci"},{"key":"997_CR23","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/j.1365-2133.1984.tb04642.x","volume":"110","author":"Farr","year":"1984","unstructured":"Farr PM, Ive FA (1984) PUVA treatment of scleromyxoedema. Br J Dermatol 110:347\u2013350","journal-title":"Br J Dermatol"},{"key":"997_CR24","first-page":"321","volume":"39","author":"Kaufman","year":"1987","unstructured":"Kaufman D, Truha AP, Roenigk HH Jr (1987) Scleromyxedema: systemic manifestations and cosmetic improvement with dermabrasion. Cutis 39:321\u2013324","journal-title":"Cutis"},{"key":"997_CR25","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0190-9622(88)70199-1","volume":"19","author":"Milam","year":"1988","unstructured":"Milam CP, Cohen LE, Fenske NA, Ling NS (1988) Scleromyxedema: therapeutic response to isotretinoin in three patients. J Am Acad Dermatol 19:469\u2013477","journal-title":"J Am Acad Dermatol"},{"key":"997_CR26","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/0190-9622(91)70132-L","volume":"24","author":"Hisler","year":"1991","unstructured":"Hisler BM, Savoy LB, Hashimoto K (1991) Improvement of scleromyxedema associated with isotretinoin therapy. J Am Acad Dermatol 24:854\u2013857","journal-title":"J Am Acad Dermatol"},{"key":"997_CR27","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0190-9622(99)70471-8","volume":"40","author":"Tschen","year":"1999","unstructured":"Tschen JA, Chang JR (1999) Scleromyxedema: treatment with interferon alfa. J Am Acad Dermatol 40:303\u2013307","journal-title":"J Am Acad Dermatol"},{"key":"997_CR28","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/j.1365-2133.1996.tb03846.x","volume":"135","author":"Cohen","year":"1996","unstructured":"Cohen AM, Hodar E, David M et al (1996) Beneficial effect of granulocyte-colony stimulating factor in scleromyxedema associated with severe idiopathic neutropenia. Br J Dermatol 135:626\u2013629","journal-title":"Br J Dermatol"},{"key":"997_CR29","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/j.1365-2133.1982.tb04539.x","volume":"106","author":"Lowe","year":"1982","unstructured":"Lowe NJ, Dufton PA, Hunter RD, Vickers CF (1982) Electron-beam treatment of scleromyxoedema. Br J Dermatol 106:449\u2013453","journal-title":"Br J Dermatol"},{"key":"997_CR30","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/S0190-9622(08)80676-7","volume":"25","author":"Berkson","year":"1991","unstructured":"Berkson M, Lazarus GS, Uberti-Benz M, Rook AH (1991) Extracorporeal photochemotherapy: a potentially useful treatment for scleromyxedema. J Am Acad Dermatol 25:724","journal-title":"J Am Acad Dermatol"},{"key":"997_CR31","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1001\/archderm.1975.01630220089007","volume":"111","author":"Howsden","year":"1975","unstructured":"Howsden SM, Herndon JH Jr, Freeman RG (1975) Lich myxedematosus: a dermal infiltrative disorder responsive to cyclophosphamide therapy. Arch Dermatol 111:1325\u20131330","journal-title":"Arch Dermatol"},{"key":"997_CR32","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1111\/j.1365-4362.1978.tb05989.x","volume":"17","author":"Jessen","year":"1978","unstructured":"Jessen RT, Straight M, Becker LE (1978) Lichen myxedematosus: treatment with cyclophosphamide. Int J Dermatol 17:833\u2013839","journal-title":"Int J Dermatol"},{"key":"997_CR33","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1093\/ajcp\/69.4.446","volume":"69","author":"Verity","year":"1978","unstructured":"Verity MA, Toop J, McAdam LP, Pearson CM (1978) Scleromyxedema myopathy: histochemical and electron microscopic observations. Am J Clin Pathol 69:446\u2013451","journal-title":"Am J Clin Pathol"},{"key":"997_CR34","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1002\/art.1780200412","volume":"20","author":"McAdam","year":"1977","unstructured":"McAdam LP, Pearson CM, Pitts WH et al (1977) Papular mucinosis with myopathy, arthritis, and eosinophilia: a histopathologic study. Arthritis Rheum 20:989\u2013996","journal-title":"Arthritis Rheum"},{"key":"997_CR35","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/S0190-9622(08)81176-0","volume":"22","author":"Keong","year":"1990","unstructured":"Keong CH, Asaka Y, Fukuro S et al (1990) Successful treatment of scleromyxedema with plasmapheresis and immunosuppression. J Am Acad Dermatol 22:842\u2013844","journal-title":"J Am Acad Dermatol"},{"key":"997_CR36","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1001\/archderm.1969.01610190057010","volume":"99","author":"Feldman","year":"1969","unstructured":"Feldman P, Shapiro L, Pick AI, Slatkin MH (1969) Scleromyxedema: a dramatic response to melphalan (in German). Arch Dermatol 99:51\u201356","journal-title":"Arch Dermatol"},{"key":"997_CR37","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1001\/archderm.1979.04010030003002","volume":"115","author":"Harris","year":"1979","unstructured":"Harris RB, Perry HO, Kyle RA, Winkelmann RK (1979) Treatment of scleromyxedema with melphalan. Arch Dermatol 115:295\u2013299","journal-title":"Arch Dermatol"},{"key":"997_CR38","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jaad.2004.03.023","volume":"51","author":"Horn","year":"2004","unstructured":"Horn KB, Horn MA, Swan J et al (2004) A complete and durable clinical response to high-dose dexamethasone in a patient with scleromyxedema. J Am Acad Dermatol 51:120\u2013123","journal-title":"J Am Acad Dermatol"},{"key":"997_CR39","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.jaad.2005.04.012","volume":"53","author":"Kreuter","year":"2005","unstructured":"Kreuter A, Altmeyer P (2005) High-dose dexamethasone in scleromyxedema: report of 2 additional cases. J Am Acad Dermatol 53:739\u2013740","journal-title":"J Am Acad Dermatol"},{"key":"997_CR40","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/j.1468-3083.2005.01134.x","volume":"19","author":"Wojas-Pelc","year":"2005","unstructured":"Wojas-Pelc A, B\u0142aszczyk M, Gli\u0144ska M, Jab\u0142o\u0144ska S (2005) Tumorous variant of scleromyxedema. Successful therapy with intravenous immuno-globulins. J Eur Acad Dermatol Venereol 19:462\u2013465","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"997_CR41","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s10227-005-0137-9","volume":"9","author":"Majeski","year":"2005","unstructured":"Majeski C, Taher M, Grewal P et al (2005) Combination oral prednisone and intravenous immunoglobulin in the treatment of scleromyxedema. J Cutan Med Surg 9:99\u2013104","journal-title":"J Cutan Med Surg"},{"key":"997_CR42","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s00105-006-1261-1","volume":"58","author":"Topf","year":"2007","unstructured":"Topf S, Simon M Jr, Schell H, L\u00fcftl M (2007) Marked improvement in scleromyxedema with high-dose intravenous immunoglobulin. Hautarzt 58:525\u2013528","journal-title":"Hautarzt"},{"key":"997_CR43","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1111\/j.1365-2133.2007.08169.x","volume":"157","author":"Gholam","year":"2007","unstructured":"Gholam P, Hartmann M, Enk A (2007) Arndt-Gottron scleromyxoedema: successful therapy with intravenous immunoglobulins. Br J Dermatol 157:1058\u20131060","journal-title":"Br J Dermatol"},{"key":"997_CR44","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.semarthrit.2007.10.015","volume":"38","author":"Efthimiou","year":"2008","unstructured":"Efthimiou P, Blanco M (2008) Intravenous gammaglobulin and thalidomide may be an effective therapeutic combination in refractory scleromyxedema: case report and discussion of the literature. Semin Arthritis Rheum 38:188\u2013194","journal-title":"Semin Arthritis Rheum"},{"key":"997_CR45","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1067\/mjd.2000.104001","volume":"43","author":"Lister","year":"2000","unstructured":"Lister RK, Jolles S, Whittaker S et al (2000) Scleromyxedema: response to high-dose intravenous immunoglobulin (hdIVIg). J Am Acad Dermatol 43:403\u2013408","journal-title":"J Am Acad Dermatol"},{"key":"997_CR46","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/j.1468-3083.2006.01951.x","volume":"21","author":"K\u00f6rber","year":"2007","unstructured":"K\u00f6rber A, Franckson T, Grabbe S, Dissemond J (2007) Successful therapy of scleromyxoedema Arndt-Gottron with low-dose intravenous immunoglobulin. J Eur Acad Dermatol Venereol 21:553\u2013554","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"997_CR47","doi-asserted-by":"crossref","first-page":"248","DOI":"10.4103\/0378-6323.41372","volume":"74","author":"Binitha","year":"2008","unstructured":"Binitha MP, Nandakumar G, Thomas D (2008) Suspected cardiac toxicity to intravenous immunoglobulin used for treatment of scleromyxedema. Indian J Dermatol Venereol Leprol 74:248\u2013250","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"997_CR48","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.annder.2008.06.011","volume":"136","author":"Lopez","year":"2009","unstructured":"Lopez L, Wierzbicka-Hainaut E, Villers A, Guillet G (2009) Efficacy of intravenous immunoglobulin in Arndt-Gottron scleromyxedema. Ann Dermatol Venereol 136:330\u2013336","journal-title":"Ann Dermatol Venereol"},{"key":"997_CR49","first-page":"15","volume":"19","author":"Manousaridis","year":"2010","unstructured":"Manousaridis I, Loeser C, Goerdt S, Hassel JC (2010) Managing scleromyxedema with intravenous immunoglobulin: acute worsening of scleromyxedema with biclonal gammopathy. Acta Dermatovenerol Alp Panonica Adriat 19:15\u201319","journal-title":"Acta Dermatovenerol Alp Panonica Adriat"},{"key":"997_CR50","first-page":"1071","volume":"137","author":"Feasel","year":"2001","unstructured":"Feasel AM, Donato ML, Duvic M (2001) Complete remission of scleromyxedema following autologous stem cell transplantation. Arch Dermatol 137:1071\u20131072","journal-title":"Arch Dermatol"},{"key":"997_CR51","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1182\/blood-2004-12-4870","volume":"107","author":"Donato","year":"2006","unstructured":"Donato ML, Feasel AM, Weber DM et al (2006) Scleromyxedema: role of high-dose melphalan with autologous stem cell transplantation. Blood 107:463\u2013466","journal-title":"Blood"},{"key":"997_CR52","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1001\/archderm.141.10.1277","volume":"141","author":"Lacy","year":"2005","unstructured":"Lacy MQ, Hogan WJ, Gertz MA et al (2005) Successful treatment of scleromyxedema with autologous peripheral blood stem cell transplantation. Arch Dermatol 141:1277\u20131282","journal-title":"Arch Dermatol"},{"key":"997_CR53","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1182\/blood-2006-01-0186","volume":"108","author":"Illa","year":"2006","unstructured":"Illa I, Torre C de la, Rojas-Garcia R et al (2006) Steady remission of scleromyxedema 3 years after autologous stem cell transplantation: an in vivo and in vitro study. Blood 108:773\u2013774","journal-title":"Blood"},{"key":"997_CR54","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1468-3083.2006.01814.x","volume":"21","author":"Iranzo","year":"2007","unstructured":"Iranzo P, L\u00f3pez-Lerma I, Blad\u00e9 J et al (2007) Scleromyxoedema treated with autologous stem cell transplantation. J Eur Acad Dermatol Venereol 21:129\u2013130","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"997_CR55","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2165\/00128071-200809040-00008","volume":"9","author":"Ataergin","year":"2008","unstructured":"Ataergin S, Arpaci F, Demiriz M, Ozet A (2008) Transient efficacy of double high-dose chemotherapy and autologous peripheral stem cell transplantation, immunoglobulin, thalidomide, and bortezomib in the treatment of scleromyxedema. Am J Clin Dermatol 9:271\u2013273","journal-title":"Am J Clin Dermatol"},{"key":"997_CR56","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/bmt.2008.148","volume":"42","author":"Cheng","year":"2008","unstructured":"Cheng T, Gnanakumar V, Hegedus C, Stewart DA (2008) Complete and durable remission in a patient with life-threatening scleromyxedema treated with high-dose melphalan and BU with auto-SCT. Bone Marrow Transplant 42:215\u2013217","journal-title":"Bone Marrow Transplant"},{"key":"997_CR57","doi-asserted-by":"crossref","unstructured":"Bos R, Waal EG de, Kuiper H et al (2011) Thalidomide and dexamethasone followed by autologous stem cell transplantation for scleromyxoedema. Rheumatology (Oxford) 50:1925\u20131926","DOI":"10.1093\/rheumatology\/ker209"},{"key":"997_CR58","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1001\/archderm.140.3.277","volume":"140","author":"Caradonna","year":"2004","unstructured":"Caradonna S, Jacobe H (2004) Thalidomide as a potential treatment for scleromyxedema. Arch Dermatol 140:277\u2013280","journal-title":"Arch Dermatol"},{"key":"997_CR59","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jaad.2004.01.058","volume":"51","author":"Sansbury","year":"2004","unstructured":"Sansbury JC, Cocuroccia B, Jorizzo JL et al (2004) Treatment of recalcitrant scleromyxedema with thalidomide in 3 patients. J Am Acad Dermatol 51:126\u2013131","journal-title":"J Am Acad Dermatol"},{"key":"997_CR60","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1159\/000093856","volume":"213","author":"Jacob","year":"2006","unstructured":"Jacob SE, Fien S, Kerdel FA (2006) Scleromyxedema, a positive effect with thalidomide. Dermatology 213:150\u2013152","journal-title":"Dermatology"},{"key":"997_CR61","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1111\/j.1468-3083.2006.01761.x","volume":"20","author":"Thyssen","year":"2006","unstructured":"Thyssen JP, Zachariae C, Menn\u00e9 T (2006) Successful treatment of scleromyxedema using thalidomide. J Eur Acad Dermatol Venereol 20:1396\u20131397","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"997_CR62","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1159\/000096914","volume":"214","author":"Amini-Adle","year":"2007","unstructured":"Amini-Adle M, Thieulent N, Dalle S et al (2007) Scleromyxedema: successful treatment with thalidomide in two patients. Dermatology 214:58\u201360","journal-title":"Dermatology"},{"key":"997_CR63","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/j.1468-3083.2007.02420.x","volume":"22","author":"Martins","year":"2008","unstructured":"Martins A, Paiva Lopes MJ et al (2008) Scleromyxedema\u2013thalidomide therapy. J Eur Acad Dermatol Venereol 22:622\u2013624","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"997_CR64","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1468-3083.2008.02766.x","volume":"23","author":"Wu","year":"2009","unstructured":"Wu MY, Hong JB, Yang CC et al (2009) Scleromyxedema with myopathy was successfully treated by thalidomide. J Eur Acad Dermatol Venereol 23:189\u2013190","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"997_CR65","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/j.1365-2230.2008.02744.x","volume":"33","author":"Peter","year":"2008","unstructured":"Peter LM, Ammoury A, Chiavassa-Gandois H et al (2008) Scleromyxoedema with associated peripheral neuropathy: successful treatment with thalidomide. Clin Exp Dermatol 33:606\u2013610","journal-title":"Clin Exp Dermatol"},{"key":"997_CR66","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.annder.2010.08.011","volume":"137","author":"Le","year":"2010","unstructured":"Le Moigne M, Mazereeuw-Hautier J, Bonnetblanc JM et al (2010) Clinical characteristics, outcome of scleromyxoedema: a retrospective multicentre study. Ann Dermatol Venereol 137:782\u2013788","journal-title":"Ann Dermatol Venereol"},{"key":"997_CR67","doi-asserted-by":"crossref","first-page":"631","DOI":"10.2340\/00015555-0731","volume":"89","author":"Laimer","year":"2009","unstructured":"Laimer M, Namberger K, Massone C et al (2009) Vincristine, idarubicin, dexamethasone and thalidomide in scleromyxoedema. Acta Derm Venereol 89:631\u2013635","journal-title":"Acta Derm Venereol"},{"key":"997_CR68","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.annder.2009.11.010","volume":"137","author":"Sillard","year":"2010","unstructured":"Sillard L, Passeron T, Cardot-Leccia N et al (2010) Efficacy of intravenous immunoglobulin in the treatment of scleromyxoedema. Ann Dermatol Venereol 137:48\u201352","journal-title":"Ann Dermatol Venereol"},{"key":"997_CR69","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.leukres.2011.07.021","volume":"35","author":"Migkou","year":"2011","unstructured":"Migkou M, Gkotzamanidou M, Terpos E et al (2011) Response to bortezomib of a patient with scleromyxedema refractory to other therapies. Leuk Res 35:209\u2013211","journal-title":"Leuk Res"},{"key":"997_CR70","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1002\/ajh.22131","volume":"86","author":"Fett","year":"2011","unstructured":"Fett NM, Toporcer MB, Dalmau J et al (2011) Scleromyxedema and dermato-neuro syndrome in a patient with multiple myeloma effectively treated with dexamethasone and bortezomib. Am J Hematol 86:893\u2013896","journal-title":"Am J Hematol"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-012-0997-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00393-012-0997-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-012-0997-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,27]],"date-time":"2024-04-27T01:07:01Z","timestamp":1714180021000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00393-012-0997-5"}},"subtitle":["Eine chronisch progressive Systemerkrankung","A chronic progressive systemic disease"],"short-title":[],"issued":{"date-parts":[[2012,7,19]]},"references-count":70,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["997"],"URL":"https:\/\/doi.org\/10.1007\/s00393-012-0997-5","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,7,19]]}}}